95 PEAK and PINNACLE – Key question: Why is mean change in BCVA the primary endpoint and not ≥15 letter gainers or losers? Evaluating mean change in BCVA as the primary endpoint maximizes the potential for both studies to be positive 0 5 10 15 0 4 8 12 16 20 24 5 mg 10 mg ETDRS Letters 5 mg 8 8 8 8 8 10 mg 10 10 10 10 10 N values APEX 2 Mean Change in BCVA in patients completing Week 12 Weeks 0 5 10 15 0 4 8 12 16 20 24 Sham ETDRS Letters Cross-trial assessments should be interpreted with caution due to various limitations 1. Yeh S, et al. Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial. Ophthalmology. 2020 Jul;127(7):948-955 2. Preliminary results. As the APEX study is ongoing, final results may be different due to additional data collection or data cleaning. Includes only patients in the per protocol set that completed the Week 12 visit by the cutoff date of 14-Jul-25 and meet all the eligibility criteria. Excludes one patient in the 10 mg dose with a significant epiretinal membrane at baseline (exclusion criterion) PEACHTREE 1 Mean Change in BCVA in sham treated patients